On tonight’s MAD MONEY show on CNBC, Cramer reviewed what the state of the stent market will be.
There is a meeting Thursday at the FDA where the FDA is going to make a recommendation or decision on stents and the approval of them. Cramer thinks that stents will stay and the FDA may either ask for more data or just make token comments.
Both Boston Scientific (BSX) & J&J (JNJ) have been down on the possibility that an FDA decision "could" go against them. Cramer said that BSX is the riskier of the two because it has more business leveraged, and JNJ has diversified mush of its operations. Cramer prefers BSX for a trade, but warned again that this has risks.BSX traded up almost 4% today to $16.56, but traded up another 0.9% to$16.70 after Cramer discussed this.
By the way, Cramer left off two important companies here. SurModics (SRDX) provides the stent polymer coating for J&J and Angiotech (ANPI) makes the stent polymer coating for Boston Scientific. Those would both be very leveraged, with more downside if FDA pans the stent markets.
Jon C. Ogg
December 5, 2006
Credit Card Companies Are Doing Something Nuts
Credit card companies are at war. The biggest issuers are handing out free rewards and benefits to win the best customers.
It’s possible to find cards paying unlimited 1.5%, 2%, and even more today. That’s free money for qualified borrowers, and the type of thing that would be crazy to pass up. Those rewards can add up to thousands of dollars every year in free money, and include other benefits as well.
We’ve assembled some of the best credit cards for users today. Don’t miss these offers because they won’t be this good forever.
Flywheel Publishing has partnered with CardRatings for our coverage of credit card products. Flywheel Publishing and CardRatings may receive a commission from card issuers.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
